# Post-Operative Nausea & Vomiting 

---

## I. Scope & Definitions
- **PONV**: nausea and/or vomiting within 24–48 h of anesthesia/surgery.
- Post-op N/V may be **benign (PONV, medication-related)** or indicate **complication** (ileus, SBO, anastomotic leak, aspiration, intracranial process).
- Goals: **stabilize → identify driver (PONV vs obstructive/medical) → treat using class-based antiemetics and prokinetics → prevent recurrence**.

---

## II. First-Principles Framework (etiology buckets)
- **CNS/vestibular**: anesthetics, opioids, migraine, motion sensitivity.
- **GI motility/obstruction**: ileus, **SBO**, delayed gastric emptying; anastomotic complications if toxic.
- **Chemical/metabolic**: opioids, antibiotics, iron, uremia (missed dialysis), DKA, pregnancy.
- **Risk factors for PONV (Apfel)**: **female**, **non-smoker**, **prior PONV/motion sickness**, **post-op opioids** (0–4 points ≈ 10/20/40/60% risk).

---

## III. Stepwise Evaluation
**Step 1 – Rapid stabilization**
- Upright position; **NPO** if active emesis; bedside suction.
- O₂ if SpO₂ < 92%; protect airway if aspiration risk.
- IV crystalloid; **correct electrolytes** (targets: **K⁺ ≥ 4.0**, **Mg²⁺ ≥ 2.0**).

**Step 2 – Focused Hx/Exam**
- Timing (PACU vs POD 2–3), emesis character (bilious/feculent), distension/tenderness, flatus/BM, prior PONV, migraine/vestibular symptoms, opioid dose.

**Step 3 – Targeted Workup (as indicated)**
- Labs: BMP (K/Mg/Ca), glucose; ± lactate if ill; pregnancy test when relevant.
- Imaging: **upright/supine KUB** for ileus/SBO → **CT A/P with IV contrast** if concerning.
- **ECG** if multiple QT-prolonging meds or baseline risk.

---

## IV. Universal Early Actions
- **NPO**, IV fluids, electrolyte repletion to targets.
- **Opioid-sparing** analgesia (acetaminophen, regional, NSAIDs if safe).
- IS and early mobilization when safe; aspiration precautions.

---

## V. Antiemetic & Prokinetic Options (choose by class; avoid duplicating the same class if already used)
**5-HT3 antagonist**
- **Ondansetron** 4–8 mg IV/PO q8h PRN  
  *Avoid high total IV doses; **do not use 32 mg IV single dose**. QT caution—correct K/Mg; ECG if high-risk.*

**D2 antagonists**
- **Prochlorperazine** 5–10 mg IV/PO q6h PRN  
- **Haloperidol** 0.5–2 mg IV/IM q6–8h PRN *(QT/TdP caution)*  
- **Droperidol** 0.625–1.25 mg IV once *(boxed warning for QT; use lowest effective dose with ECG and corrected K/Mg)*

**Antihistamine/anticholinergic**
- **Promethazine** 12.5–25 mg PO/IM/IV q6h PRN *(sedation, anticholinergic; avoid IV extravasation)*  
- **Scopolamine** 1.5 mg **TD patch** q72h *(apply pre- or early post-op in high risk)*

**Steroid**
- **Dexamethasone** 4–8 mg IV *(best as prophylaxis at induction; can use if not already given)*

**NK-1 antagonist**
- **Aprepitant** 40 mg PO *(often prophylaxis; consider refractory per institutional protocol)*

**Prokinetic**
- **Metoclopramide** 10 mg IV/PO q6h PRN *(avoid if mechanical obstruction; EPS/QT caution)*  
- **Erythromycin** 250 mg IV/PO q6–8h (short course) for foregut dysmotility *(QT/cytochrome interactions; local practice varies)*

---

## VI. PONV Prophylaxis (use Apfel risk)
- **0–1 risk factor**: 1 agent (e.g., ondansetron **or** dexamethasone).  
- **2 risk factors**: 2 different classes.  
- **3–4 risk factors**: ≥2 classes (often **three**: dexamethasone + 5-HT3 + scopolamine **or** droperidol).  
- **Rescue rule**: if N/V occurs despite prophylaxis, **treat with a different class** than those already given.

---

## VII. Rescue Ladder (when symptoms occur or persist)
1. **If no prophylaxis was given**:  
   - Start **one agent** (e.g., **ondansetron 4 mg IV**). Reassess in **30–60 min**.
2. **If persistent symptoms**:  
   - Add **a second agent from a different class** (e.g., **promethazine 12.5–25 mg IV** *or* **prochlorperazine 5–10 mg IV**).  
3. **If still symptomatic**:  
   - Add **a third class** (e.g., **dexamethasone 4–8 mg IV** if not yet given, **or** **droperidol 0.625–1.25 mg IV** with ECG and corrected K/Mg).  
4. **If impaired motility suspected and no mechanical obstruction**:  
   - Add **metoclopramide 10 mg IV q6h** (prokinetic), continue electrolyte optimization, minimize opioids.  
5. **Refractory/high-risk**:  
   - Consider **NK-1 antagonist (aprepitant 40 mg PO)** per formulary; review for drug interactions.  
6. **At any step, if red flags appear** (see Section X):  
   - **Escalate** evaluation for **ileus/SBO/leak** and proceed to decompression pathway.

---

## VIII. Ileus / SBO Decompression Pathway
- **Ileus likely** (distension, minimal pain, no flatus/BM): NPO, IV fluids, correct K/Mg, minimize opioids, chew gum, early ambulation, **metoclopramide** if no contraindication.  
- **High-grade obstruction or persistent large-volume emesis**: **NG tube** to low continuous suction, resuscitate, **CT A/P with IV contrast**, urgent surgical review.

---

## IX. Special Situations
- **Missed dialysis / uremia**: antiemetics are symptomatic only—**nephrology for urgent dialysis**.  
- **Pregnancy possible**: test prior to certain meds; tailor regimen.  
- **Migraine phenotype**: add migraine therapy (e.g., triptan/NSAID) when safe.  
- **QT safety**: avoid stacking QT-prolonging agents; correct K/Mg before **droperidol/haloperidol/high-dose 5-HT3**; obtain ECG in at-risk patients.

---

## X. Red Flags — Call Senior / Escalate Early
- Bilious or **feculent emesis**; severe distension; peritonitis; fever/tachycardia.  
- **No flatus/BM** with worsening distension/pain (ileus/SBO).  
- **Hematemesis**; aspiration; **SpO₂ < 92%** despite O₂.  
- **Refractory N/V** despite ≥2 different antiemetic classes.  
- Severe electrolyte derangements, AKI, or dehydration not improving.

---

## XI. Quick Reference — Antiemetic/Prokinetic Doses

| Class | Medication | Typical Dose & Route | Key Safety Notes |
|---|---|---|---|
| 5-HT3 | Ondansetron | **4–8 mg IV/PO q8h PRN** | **Do not use 32 mg IV**; QT caution; correct K/Mg |
| D2 | Prochlorperazine | 5–10 mg IV/PO q6h PRN | EPS/sedation; QT caution |
| D2 | Haloperidol | 0.5–2 mg IV/IM q6–8h PRN | QT/TdP risk; ECG if high-risk |
| D2 | Droperidol | **0.625–1.25 mg IV once** | Boxed QT warning; ECG + electrolyte correction |
| H1/ACh | Promethazine | 12.5–25 mg PO/IM/IV q6h PRN | Sedation/anticholinergic; IV tissue injury risk |
| ACh | Scopolamine patch | 1.5 mg TD q72h | Avoid narrow-angle glaucoma; delirium risk |
| Steroid | Dexamethasone | 4–8 mg IV | Best prophylaxis at induction; hyperglycemia |
| NK-1 | Aprepitant | 40 mg PO | CYP interactions; formulary-dependent |
| Benzamide | Metoclopramide | **10 mg IV/PO q6h PRN** | Avoid if obstruction; EPS/QT caution |
| Macrolide | Erythromycin | 250 mg IV/PO q6–8h (short course) | QT/cytochrome interactions |

---

## XII. Intern Pearls
- Treat airway/oxygenation and **dehydration/electrolytes first**.  
- Use **risk-based prophylaxis** and **rescue from a different class**.  
- Pair **N/V + distension + no flatus** with **imaging and early NG** rather than stacking antiemetics.  
- Minimize opioids; mobilize early.

---

## XIII. References
1. Gan TJ, et al. **Fourth Consensus Guidelines for the Management of PONV (2020).** *Anesth Analg.* 2020;131:411–448.  
2. Apfel CC, et al. **A simplified risk score for predicting PONV.** *Anesthesiology.* 1999;91:693–700.  
3. FDA Drug Safety Communications: **Ondansetron** – removal of 32 mg IV dose; QT/TdP risk.  
4. Droperidol safety and QT guidance — contemporary reviews and labeling.
